Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00260611 · ClinicalTrials.gov registry record · Phase 2
Study of Oxaliplatin and Taxotere in Prostate Cancer
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00260611 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 34 participants.
The verdict
NCT00260611, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The primary objective for this study is to evaluate PSA response rates (response will be defined as a \> 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety).
Interventions
- DRUG Oxaliplatin
- DRUG Taxotere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00260611
The ClinicalTrials.gov registry entry for NCT00260611 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT00260611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00260611 about?
NCT00260611 is a clinical study titled "Study of Oxaliplatin and Taxotere in Prostate Cancer". The primary objective for this study is to evaluate PSA response rates (response will be defined as a \> 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity ...
What is the current status of trial NCT00260611?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2004-11. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00260611?
The interventions under investigation include: Oxaliplatin (DRUG), Taxotere (DRUG).
Who is sponsoring clinical trial NCT00260611?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.